SCHEMBL3941695

SCHEMBL3941695

CC(C)(C)OC(=O)NCCCOc1cccc(Cl)c1-c1cc(Cl)nc(N)n1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 6/20 0.55
HSP90AB1 P08238 5/20 0.55
STK17B O94768 1/20 0.44
STK17A Q9UEE5 1/20 0.44
CA12 O43570 4/20 0.43
CA1 P00915 4/20 0.43
CA2 P00918 4/20 0.43
CA9 Q16790 4/20 0.43
DRD2 P14416 1/20 0.41
ATM Q13315 1/20 0.41
SCN9A Q15858 1/20 0.41
SUCNR1 Q9BXA5 1/20 0.40
MCHR1 Q99705 1/20 0.39
ABL1 P00519 1/20 0.39
PDGFRB P09619 1/20 0.39
SRC P12931 1/20 0.39
PDGFRA P16234 1/20 0.39
MAPK14 Q16539 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4033797 0.98 HSP90AA1 (0.55) HSP90AA1HSP90AB1STK17BSTK17ACA12
SCHEMBL13753170 0.83 HSP90AA1 (0.54) HSP90AA1HSP90AB1MCHR1
SCHEMBL13744814 0.78 DRD2 (0.49) STK17BSTK17ACA12CA1CA2
SCHEMBL3949271 0.77 HSP90AA1 (0.67) HSP90AA1HSP90AB1
SCHEMBL4225202 0.77 HSP90AA1 (0.64) HSP90AA1HSP90AB1
SCHEMBL4211927 0.76 HSP90AA1 (0.73) HSP90AA1HSP90AB1
SCHEMBL3945723 0.76 HSP90AA1 (0.65) HSP90AA1HSP90AB1
SCHEMBL1683198 0.75 KMT2A (0.52) CA12CA1CA2CA9DRD2
SCHEMBL14804193 0.75 MEN1 (0.67) CA12CA1CA2CA9SCN9A
SCHEMBL17315325 0.74 NUDT1 (0.55) HSP90AA1HSP90AB1STK17BSTK17ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215777-A1 Pyrimidine Derivatives As HSP90 Inhibitors ASTEX THERAPEUTICS LTD. (GB) 2009-08-27 US disclosed
US-20090215777-A1 Pyrimidine Derivatives As HSP90 Inhibitors ASTEX THERAPEUTICS LTD. (GB) 2009-08-27 US disclosed
US-20090215777-A1 Pyrimidine Derivatives As HSP90 Inhibitors ASTEX THERAPEUTICS LTD. (GB) 2009-08-27 US disclosed
EP-2049497-A2 PYRIMIDINE DERIVATIVES AS HSP90 INHIBITORS Astex Therapeutics Limited (GB) 2009-04-22 EP disclosed
WO-2006123165-A2 PYRIMIDINE DERIVATIVES AS HSP90 INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215777-A1 Pyrimidine Derivatives As HSP90 Inhibitors HSP90AB1, HSP90AB2P, HSP90B1 HSP90AA1 4/4885HSP90AB1 1/4885STK17B 1161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.